MedTrace Logo

Sublingual Cannabidiol for Anxiety

NCT02548559 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-03-27

Study results available
· View outcomes & findings →

Summary

This is an open-label to double-blind study evaluating the effects of cannabidiol (CBD) for the treatment of anxiety in adults. Participants will use a sublingual (under-the-tongue) solution of whole plant-derived CBD or placebo three times daily for four weeks in addition to their normal treatment regimen. Participants' clinical state will be assessed weekly during the treatment period. In addition, cognitive function and measures of quality of life, sleep, and general health will be assessed at baseline and the post-treatment final visit.

Conditions

Interventions

DRUG

Full-Spectrum Cannabidiol

Full-Spectrum Cannabidiol; total daily dose of 30 mg.

DRUG

Single-Compound Cannabidiol

Single-Compound Cannabidiol; total daily dose of 30 mg.

DRUG

Placebo

Placebo solution.

Sponsors & Collaborators

  • Staci Gruber, Ph.D.

    lead OTHER

Principal Investigators

  • Staci Gruber, PhD. · Mclean Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-14
Primary Completion
2025-03-13
Completion
2025-03-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02548559 on ClinicalTrials.gov